Tema Oncology ETF Rating $26.60 +0.29 (+1.10%) Closing price 08/5/2025 03:58 PM EasternExtended Trading$26.65 +0.05 (+0.19%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.81Holdings in CANC have an aggregate rating of Moderate Buy based on 315 analyst ratings issued in the past year covering 22 companies (69.5% of the portfolio).CANC Aggregate Price Target$26.60High Prediction$26.60Average Prediction$26.60Low Prediction$26.60Holdings in CANC have an aggregate price target of $26.60 and a range of $26.60 to $26.60 covering 22 companies (69.5% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy10 Buy rating(s)Moderate Buy9 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 22 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.88%RHHBYRoche$39.420.0%N/A2.5774.74%RVMDRevolution Medicines$38.39+3.3%4.5128 of 5 stars3.00$68.91 79.5%114.68%BBIOBridgeBio Pharma$49.21+3.1%4.504 of 5 stars3.00$61.18 24.3%17Earnings ReportHigh Trading Volume4.58%MRUSMerus$67.45+0.8%3.2539 of 5 stars3.00$86.40 28.1%11News CoverageEarnings Report4.45%LLYEli Lilly and Company$766.47-0.3%4.9105 of 5 stars2.75$1,012.56 32.1%20Trending NewsUpcoming Earnings3.81%GMABGenmab A/S$22.10+0.5%3.5484 of 5 stars2.64$37.80 71.0%11Upcoming EarningsShort Interest ↑3.80%SMMTSummit Therapeutics$29.13-0.6%2.1172 of 5 stars2.79$34.67 19.0%14Positive News3.36%NUVLNuvalent$78.62+0.3%3.3594 of 5 stars3.09$119.60 52.1%11Positive News3.29%ZLABZai Lab$39.51+3.8%2.4142 of 5 stars2.80$54.28 37.4%5Positive NewsUpcoming EarningsGap Up3.26%ACLXArcellx$72.04-0.1%2.6495 of 5 stars3.13$114.31 58.7%15News CoveragePositive NewsAnalyst Upgrade3.25%EXELExelixis$37.46+1.8%4.9365 of 5 stars2.55$44.44 18.6%22Positive News3.14%ONCBeOne Medicines$307.23+1.0%0.6977 of 5 stars3.00$327.56 6.6%7Insider Trade3.14%BMYBristol Myers Squibb$45.82+0.9%4.635 of 5 stars2.33$56.38 23.0%21Trending NewsEarnings ReportAnalyst DowngradeAnalyst Revision2.99%LEGNLegend Biotech$38.42-0.1%3.8536 of 5 stars3.00$73.33 90.9%11News CoveragePositive NewsUpcoming EarningsAnalyst Upgrade2.92%AMGNAmgen$300.08-0.6%4.596 of 5 stars2.35$307.27 2.4%23Trending NewsEarnings ReportDividend Announcement2.71%ABBVAbbVie$198.53+0.7%4.5987 of 5 stars2.81$212.81 7.2%27Trending NewsEarnings ReportAnalyst Revision2.29%IDYAIDEAYA Biosciences$24.12-3.5%4.1885 of 5 stars2.77$48.09 99.4%13News CoverageEarnings Report2.13%MRKMerck & Co., Inc.$80.78+1.2%4.9919 of 5 stars2.35$107.44 33.0%20Positive News1.64%IMNMImmunome$10.85-0.9%1.9585 of 5 stars3.00$23.33 115.1%6Upcoming Earnings1.62%JANXJanux Therapeutics$25.50+6.6%2.8853 of 5 stars3.08$91.89 260.3%12News CoveragePositive News1.44%COGTCogent Biosciences$11.36-5.7%3.066 of 5 stars2.82$18.70 64.6%111.40%ARGXargenex$674.90-2.2%4.1275 of 5 stars3.10$746.81 10.7%20Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision This page (NASDAQ:CANC) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANC Stock Alerts